Genome&Company joins global pharma Lilly's TuneLab; accelerating AI drug development
Predicted impact: Low
Lilly TuneLab participation already reported several times; no financial terms given
Genome&Company지놈앤컴퍼니
314130 · KOSDAQ · ₩314130 · 지놈앤컴퍼니
₩3,900▲ ₩10 (0.26%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y +36.60%
- Market cap
- ₩204B
- Enterprise value
- ₩166B
- P/E
- —
- P/B
- 2.8×
- Dividend yield
- 0.0%
- ROE
- −57.5%
- Net margin
- −169.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−61.7% from the high
₩2,745Today: ₩3,880 – ₩4,115₩10,180
Returns
- 1W−7.5%
- 1M−19.3%
- 3M+9.4%
- 6M−38.6%
- YTD−43.3%
- 1Y+36.6%
- Volume today
- 225,871
- 0.4× the 20-day average
- Traded today
- ₩898M
- Listed shares
- 52,301,425
- EPS (12 months)
- −₩791
- Earnings yield −20.3%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 28 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Two business expansions reported: a partnership with Lilly and an acquisition in US cosmetics distribution. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-7.8% over the last month; the price is below its 20-day average.
- News impactSome6 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
Genome&Company stock overview
Genome&Company (지놈앤컴퍼니, KRX: 314130) is listed on KOSDAQ, in the Biotech & Pharma sector. Genome & Company is a Korean biopharmaceutical company that researches and develops new-target drug candidates, including antibody-drug conjugates (ADCs) and immuno-oncology therapies, using its GNOCLE drug discovery platform, and monetizes them mainly through technology licensing. Its shares closed at ₩3,900 on Oct 27, 2026, up 0.26% on the day, giving it a market value of ₩204B.
Key facts
- Market cap
- ₩204B
- Sector
- Biotech & Pharma
- Latest price change
- +0.26%
- As of
- Oct 27, 2026
- Main business
- Genome & Company is a Korean biopharmaceutical company that researches and develops new-target drug candidates, including antibody-drug conjugates (ADCs) and immuno-oncology therapies, using its GNOCLE drug discovery platform, and monetizes them mainly through technology licensing.
Quick answers about Genome&Company
- What does Genome&Company do?
- Genome & Company is a Korean biopharmaceutical company that researches and develops new-target drug candidates, including antibody-drug conjugates (ADCs) and immuno-oncology therapies, using its GNOCLE drug discovery platform, and monetizes them mainly through technology licensing. S. subsidiary List Biological Laboratories and sells microbiome-based cosmetics under the UIQ brand and health supplements to customers including cancer patients, with operations in Korea and the United States.
- What is the market cap of Genome&Company?
- The market capitalisation of Genome&Company was ₩204B at the close on Oct 27, 2026.
- Who are the largest shareholders of Genome&Company?
- According to the latest official filings, the largest reported holders are Park Han-su (9.58%, as of Aug 21, 2026); Korea Investment Partners (8.43%, as of Aug 8, 2025); Bae Ji-su (7.37%, as of Oct 28, 2025).
- When is the next earnings report from Genome&Company?
- Korean companies rarely announce results dates in advance. Based on when Genome&Company filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Genome&Company?
- Yes. The National Pension Service held 0.24% of Genome&Company shares as of Dec 31, 2021.
Company profile
Genome & Company is a Korean biopharmaceutical company that researches and develops new-target drug candidates, including antibody-drug conjugates (ADCs) and immuno-oncology therapies, using its GNOCLE drug discovery platform, and monetizes them mainly through technology licensing. It also runs a contract development and manufacturing business through its U.S. subsidiary List Biological Laboratories and sells microbiome-based cosmetics under the UIQ brand and health supplements to customers including cancer patients, with operations in Korea and the United States.
Written by AI from the company's latest annual report.
- Korean name
- 지놈앤컴퍼니
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 홍유석, 배지수, 박한수 (각자 대표이사)
- Founded
- Sep 2015
- Listed
- Dec 2020
- Listed shares
- 52,301,425
- Fiscal year ends
- Month 12
- Website
- genomecom.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Genome&Company acquires management rights of K-beauty distributor Allbloom, expanding US reach of 'Yuik'
Predicted impact: Low
Management rights acquisition of small distributor; size is small versus market value.
Genome&Company Acquires Cosmetics Distributor Allbloom, Accelerates Eulyc's U.S. Expansion
Predicted impact: Medium
Acquisition of a cosmetics distributor; deal size undisclosed but small versus revenue.
Recent filings
See allTitles in Korean until English translations are added.
Also known as: Genome&Company / 지놈앤컴퍼니 / 314130 / KRX:314130
Source: KRX statistical information